Experimental Drug Offers Hope for Rare Bone Disease:
WEDNESDAY, March 7 (HealthDay News) -- A new therapy may be the
first to offer hope for children born with a rare disease that
affects bone development, sometimes so severely that babies die
because they're missing a rib cage to protect their lungs.
The inherited disorder is called hypophosphatasia, and the new
medication is asfotase alfa. It works by replacing an enzyme that's
missing in those with hypophosphatasia. Enzymes are substances
responsible for speeding up certain chemical reactions. In
hypophosphatasia, the missing enzyme is necessary for proper bone
growth and normal metabolism.
A small study of babies and children younger than 3 who had
debilitating or life-threatening hypophosphatasia found that
treatment with asfotase alfa strengthened bones and improved lung
function. After 48 weeks of treatment, many could start bearing
weight on their legs and some infants were even taking their first
"We saw striking improvements in these patients with severe hypophosphatasia who received the enzyme replacement," said the study's lead author, Dr. Michael Whyte, medical-scientific director of the Center for Metabolic Bone Disease and Molecular Research at Shriners Hospitals for Children in St. Louis. Whyte is also a professor at Washington University School of Medicine in St. Louis, which conducted the study jointly with Shriners and other institutions.
Results of the research are published in the March 8 issue of
New England Journal of Medicine.
Severe hypophosphatasia affects about 1 in 100,000 babies born
in the United States, according to the National Library of
Medicine. It's estimated that more people may have the disease, but
in far milder forms. The severity of the disease can range from
life-threatening to simply causing dental problems in adults,
according to background information in the article.
The enzyme in hypophosphatasia that isn't available in
sufficient quantity is called alkaline phosphatase. It's
responsible for the mineralization of bones and teeth.
Mineralization is the process that causes minerals like calcium and
phosphorus to be deposited in developing bones and teeth, according
to the National Library of Medicine. Without enough alkaline
phosphatase, several other substances can build up and cause
There are no approved medical treatments for hypophosphatasia,
according to the study.
The current study involved 11 children. All were given an
initial intravenous infusion of asfotase alfa, followed by shots of
the medication three times a week.
Parents of one baby removed their child from the trial during
the initial intravenous treatment. A second baby died from an
unrelated infection after more than seven months of treatment.
The remaining nine children have received at least 18 months of
treatment with asfotase alfa.
X-rays taken at the start of the study and at weeks 24 and 48
showed significant improvement in bone formation after treatment.
In addition, the babies showed improvement in lung function,
physical skills, and in the development of intelligence, according
to the study.
The treatment was "very well tolerated," Whyte said. And, he
added, there was no evidence that the children were developing
resistance to the drug.
Treatment with asfotase alfa needs to be ongoing, and it's not
yet clear if there are long-term side effects. Whyte and his
colleagues are continuing to study the patients enrolled in this
trial. He said that he believes children born with the severe or
life-threatening form of the disease should be given this
medication, even though it's still considered experimental. The
reason, he said, is the severe form of this disease is "invariably
lethal, usually soon after birth."
Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in
New York City, said the research is promising and groundbreaking.
"They're correcting an inborn error of metabolism and mimicking
what the body does," he said. "It would be like making someone with
type 1 diabetes start making insulin on their own, rather than just
replacing it from the outside. I think this will serve as a model
for other types of diseases."
But, he added, the current patients will need to be closely
monitored as they grow, and that there is a need for further
The study was funded by Shriners Hospitals and Enobia Pharma,
which was acquired last month by Alexion Pharmaceuticals. Whyte was
a consultant for Enobia Pharma, according to a Washington
University news release.
Read more about hypophosphatasia from the
Copyright © 2012
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.